Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including R/R FL & DLBCL, reinforcing from the P-I/Ib GO29781 study […]Read More
Shots: The 4 pivotal HAVEN studies (HAVEN-1, 2, 3, 4) included pooled data from 401 people with hemophilia A with/ out factor VIII inhibitors, with a median duration efficacy period of 120.4wks. Hemlibra maintained low treated bleed rates with ABR remaining low throughout the evaluation period at 1.4. The proportion of participants who experienced 0 […]Read More
Shots: The P-III study involves assessing SB11 vs reference ranibizumab in monthly injections (0.5 mg) in 705 patients in a ratio (1:1) with nAMD while only 634 patients continued to receive treatment up to 48wks. One-year results from the P-III study demonstrated equivalence between SB11 and reference ranibizumab in patients with nAMD The study met […]Read More
2020 is a year that nobody ever thought could turn their lives upside down. The beginning of this year witnessed the worldwide onset of Coronavirus disease or COVID-19 that has till now infected millions of people around the globe killing tens of thousands. In March 2020, WHO declared it to be a pandemic. There has […]Read More
Shots: Sanofi collaborated with Google to develop an Innovation lab, containing both scientific and commercial solutions with the aim to transform future drug & healthcare services with the involvement of data analytics and techniques The agreement focuses on enhancing and accelerating Sanofi’s operational efficiency to research and develop more personalized approaches with better understanding of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
